Blood levels of immune checkpoint antibodies and their links to inflammation, cachexia, and response in lung cancer
Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
Test whether blood concentrations and how the body handles immune checkpoint antibodies relate to inflammation, weight loss (cachexia), and treatment response in adults with lung cancer starting immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Drugs / interventions | chemotherapy, nivolumab, pembrolizumab, atezolizumab, durvalumab |
| Locations | 1 site (Tours) |
| Trial ID | NCT07004868 on ClinicalTrials.gov |
What this trial studies
This is a single-center, observational project measuring blood concentrations and pharmacokinetics of various immune checkpoint inhibitor antibodies in adults with lung cancer at first administration. Investigators will collect clinical data on weight change, inflammatory markers, and treatment outcomes without changing prescribed therapy. The study will analyze relationships between antibody exposure, signs of cachexia or systemic inflammation, and subsequent clinical response or toxicity. All participants must be followed at the University Hospital (CHRU) of Tours and consent to data use.
Who should consider this trial
Good fit: Adults (≥18 years) with any histology or stage of lung cancer who are receiving their first immune checkpoint inhibitor dose and are followed at CHRU de Tours.
Not a fit: Patients already receiving ICIs before enrollment, those not followed at CHRU de Tours, or those who refuse data processing are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help tailor immunotherapy dosing and identify patients more likely to respond or to develop cachexia-related complications.
How similar studies have performed: Previous work has shown links between immune checkpoint inhibitor exposure and outcomes, but integrating detailed pharmacokinetics with inflammation and cachexia measures in lung cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age greater than or equal to 18 years * Diagnosis of lung cancer, any histology, any stage * Treatment with Ab ICI, with or without chemotherapy * 1st administration of Ab ICI Exclusion Criteria: * Patient not followed at the CHRU de Tours * Person under protective supervision * Opposition to data processing
Where this trial is running
Tours
- university hospital, Tours — Tours, France (Recruiting)
Study contacts
- Principal investigator: Marion FERREIRA, Dr — University Hospital, Tours
- Study coordinator: Marion FERREIRA, Dr
- Email: marion.ferreira@chu-tours.fr
- Phone: 0247471640
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.